Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST HER2 substudy of tucatinib + trastuzumab in advanced solid tumors
ACTRN12620000767909Phase 2Active, not recruiting
- Sponsor
- University of Sydney
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib and trastuzumab in Nonhematologic neoplasms and cancer, sponsored by University of Sydney. Primary endpoint: Disease control. Started Feb 2022; status: active, not recruiting.
02
Drugs
tucatinibtrastuzumab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on ACTRN12620000767909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000767909.